egenesis

Restoring life after organ failure.

eGenesis is a biotechnology company committed to using its multiplex gene editing and genome engineering platform to revolutionize the treatment of organ failure. We believe that cross-species transplantation has the potential to end waitlist mortality and remove supply as a barrier to transplant. We have built a porcine genome engineering platform using advanced gene editing to create donor animals compatible for human transplantation. Our approach focuses on three classes of genetic edits to address retroviral risk and improve immunologic as well as molecular compatibility with human recipients.

Origin	Harvard University, 2016
Headquarters	Cambridge, MA
Development Stage	Clinical
Capital Raised	$463M
Last Financing	$200M (3Q24)

18M

People globally suffer from organ failure

THE VAST MAJORITY WILL DIE WAITING FOR A TRANSPLANT

- **800K** Americans suffer from kidney failure
- **330K** Americans with acute liver decompensation
- **300K** Americans suffer end-stage heart failure

$80B+

Annual U.S. healthcare spend across end-stage organ disease

Transformational Progress Since Inception

2017 → 2025

- First successful production of donors with retroviral inactivation (Science, 2017)
- Produced first transgenic donor carrying 3 classes of edits addressing historical challenges that impeded cross-species transplantation (2021)
- Published landmark preclinical study (Nature, 2023) showing most extensive xenotransplant data and durable recipient survival
- Supplied EGEN-2784 kidney for world's first pig to living human kidney transplant (March 2024)
- Achieved record of 271 days dialysis independence for second patient to receive EGEN-2784 kidney (2025)

Upcoming Milestones

2026 — Next 18 Months →

- **EGEN-2784** **KIDNEY**
  Initiation of 33-patient Phase 1/2/3 study of patients with kidney failure waitlisted for transplant. Demonstration of early clinical proof of concept (6 months dialysis independence)
- **EGEN-5784 ELC** **LIVER**
  Completion of 20-patient Phase 1 study and demonstration of clinical proof of concept in ACLF patients
- **EGEN-4467** **HEART**
  Completion of additional nonclinical studies to support IND filing and clarification of regulatory pathway for initial indication.

Team

Experienced team of scientific, technical, and operational leaders with commitment to revolutionizing the treatment of organ failure

Mike Curtis, Ph.D. PRESIDENT & CHIEF EXECUTIVE OFFICER
Jay Barth, M.D. CHIEF MEDICAL OFFICER
Susan Low, Ph.D. HEAD OF DEVELOPMENT
Jennifer Bergheiser CHIEF BUSINESS OFFICER
Wenning Qin, Ph.D. SVP, INNOVATION
Elizabeth Roberts CHIEF PEOPLE OFFICER

Learn more **egenesisbio.com** Get in touch **investors@egenesisbio.com**

egenesis

From lives on hold to future within reach.

Since 2024, we have transplanted 4 patients with our lead product for kidney failure, EGEN-2784, beginning with the first-ever transplant of a porcine kidney in a living human recipient in 2024. Our pioneering patients will continue to propel this innovation forward.

+52
DAYS

Restored kidney function



+271
DAYS

Restored kidney function

+214
DAYS & COUNTING

Transplanted on June 14, 2025

Restored kidney function



+53
DAYS & COUNTING

Transplanted on Nov 22, 2025

Restored kidney function

Platform | Genome Modifications

Inactivation

Pathogen Safety	Inactivation of porcine retroviruses

Knock-outs

Elimination of Hyperacute Rejection	$GGTA_1$ B4GalNT2 CMAH

Knock-ins

Coagulation	PROCR, THBD
Inflammation/Apoptosis	HMOX1, TNFAIP3
Innate Immunity	CD47
Complement	CD46, CD55

Pipeline



EGEN-2784 **KIDNEY**

- IND clearance to conduct Phase 1/2/3 study in patients over 50 and waitlisted for transplant
- 4 transplants completed to date under Expanded Access
- Achieved record of 271 days dialysis independence

EGEN-5784 ELC **LIVER**

- IND clearance to conduct Phase 1 study in patients with acute liver decompensation
- Potential to bridge patients to transplant/native recovery
- Proof of concept established in hepatectomized, decedent patient

EGEN-4467 **HEART**

- Achieved 2 years graft function in baboon recipient; longest known porcine orthotopic transplant
- Exploring development pathways with FDA